Flow Diverter Patents: Who Leads, Where the Gaps Are 2026
Flow diverter patents for intracranial aneurysms: leaders, filing trends and open claim space
Concentrated at the top. The top 5 assignees hold 254 of 499 records in scope (50.9%), and the top 10 hold 346 (69.3%) – a narrow group has shaped most of the claim territory. Annual filings climbed from 22 in 2017 to a peak of 49 in 2022, then fell to 25 by 2024 – a -34% change over that three-year window. Because publication typically lags filing by around 18 months, the 2025 and 2026 figures (down to 4 for the partial year) understate real activity and should not be read as a slowdown on their own.
- 1COVIDIEN LP137
- 2PULSAR VASCULAR INC35
- 3MONARCH BIOSCIENCES INC33
- 4MEDINA MEDICAL INC27
- 5INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)22
See the full flow diverters for intracranial aneurysms analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about flow diverter patents
Who holds the most patents on flow diverters for intracranial aneurysms?
One assignee leads the field with 137 of the 499 records in scope, well ahead of the fifth-ranked filer at 22. The leadership tier overall is a cluster rather than a single monopoly: the top 5 assignees combine for 50.9% of all records, and the top 10 reach 69.3%. Beyond that group, the ranking extends across 85 companies total, many with only a handful of filings, so the field has both a concentrated core and a long, active tail.
Is flow diverter patent filing activity growing or slowing down?
Filing volume rose steadily from 22 records in 2017 to a peak of 49 in 2022, then declined to 25 by 2024 – a -34% change over that three-year span. Because patent publication typically lags actual filing by around 18 months, the lower figures recorded for 2025 and 2026 are incomplete and should not yet be read as a genuine slowdown. 2024 is the most recent year in this dataset that can reasonably be treated as complete.
What technology areas do flow diverter patents cover most?
The largest concentration sits in mechanical device claims: A61B (diagnosis & surgery) appears in 54.1% of the 499 records and A61F (implants & prostheses) in 41.9%. Sterilising and disinfecting processes under A61L, relevant to biocompatibility and endothelialization performance, appear in 27.7% of records. Pharmacological classes covering drug-eluting or antiplatelet-related chemistry are present but much thinner, each under 10% of records, which points to comparatively open claim space in coating and drug-delivery chemistry relative to frame and implant geometry.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Flow Diverters for Intracranial Aneurysms covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.